68 related articles for article (PubMed ID: 35235871)
1. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract][Full Text] [Related]
2. Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries.
Corbacho B; Drummond M; Santos R; Jones E; Borràs JM; Mestre-Ferrandiz J; Espín J; Henry N; Prat A
Eur J Health Econ; 2020 Jun; 21(4):621-634. PubMed ID: 32026155
[TBL] [Abstract][Full Text] [Related]
3. Determinants of utilisation differences for cancer medicines in Belgium, Scotland and Sweden.
Ferrario A
Eur J Health Econ; 2017 Dec; 18(9):1095-1105. PubMed ID: 27942986
[TBL] [Abstract][Full Text] [Related]
4. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.
Yang WW; Juan YC; Wu GH; Pwu RF
Drug Saf; 2024 Apr; 47(4):289-299. PubMed ID: 38113017
[TBL] [Abstract][Full Text] [Related]
5. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
Adkins EM; Nicholson L; Floyd D; Ratcliffe M; Chevrou-Severac H
Clinicoecon Outcomes Res; 2017; 9():327-342. PubMed ID: 28652787
[TBL] [Abstract][Full Text] [Related]
6. Challenges for children and adolescents with cancer in Europe: the SIOP-Europe agenda.
Vassal G; Fitzgerald E; Schrappe M; Arnold F; Kowalczyk J; Walker D; Hjorth L; Riccardi R; Kienesberger A; Jones KP; Valsecchi MG; Janic D; Hasle H; Kearns P; Petrarulo G; Florindi F; Essiaf S; Ladenstein R
Pediatr Blood Cancer; 2014 Sep; 61(9):1551-7. PubMed ID: 24706509
[TBL] [Abstract][Full Text] [Related]
7. Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement.
Sehdev SR; Rawson NSB; Aseyev OI; Buick CJ; Butler MO; Edwards S; Gill S; Gotfrit JM; Hsia CC; Juergens RA; Manna M; McCarthy JS; Mukherjee SD; Snow SL; Spadafora S; Stewart DJ; Wentzell JR; Wong RPW; Zalewski PG
Curr Oncol; 2024 Mar; 31(4):1803-1816. PubMed ID: 38668039
[TBL] [Abstract][Full Text] [Related]
8. Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
Ruof J; Staab T; Dintsios CM; Schröter J; Schwartz FW
Health Econ Rev; 2016 Dec; 6(1):46. PubMed ID: 27687714
[TBL] [Abstract][Full Text] [Related]
9. Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action.
Sehdev S; Gotfrit J; Elias M; Stein BD
Curr Oncol; 2024 Mar; 31(3):1460-1469. PubMed ID: 38534943
[TBL] [Abstract][Full Text] [Related]
10. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer - An ACCELERATE Multistakeholder Consensus.
de Rojas T; Chiodin D; Pearson ADJ; Heenen D; Adamson P; Caron H; Vassal G
Clin Pharmacol Ther; 2024 Jan; 115(1):36-41. PubMed ID: 37885401
[TBL] [Abstract][Full Text] [Related]
11. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
Staab T; Isbary G; Amelung VE; Ruof J
BMC Health Serv Res; 2016 Nov; 16(1):651. PubMed ID: 27842592
[TBL] [Abstract][Full Text] [Related]
12. Child healthcare in Europe, local diversities and collective potentials: A study of the European Paediatric Association/Union of National European Paediatric Societies and Associations.
Pettoello-Mantovani M; Pop TL; Hoey H
Turk Pediatri Ars; 2020; 55(Suppl 1):1-3. PubMed ID: 32963475
[TBL] [Abstract][Full Text] [Related]
13. Should the European Medicines Agency consider ageing a disease?
Marín Penella G
Bioethics; 2024 Jun; 38(5):431-437. PubMed ID: 38165401
[TBL] [Abstract][Full Text] [Related]
14. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
15. Target therapy for high-risk neuroblastoma treatment: integration of regulatory and scientific tools is needed.
Ceci A; Conte R; Didio A; Landi A; Ruggieri L; Giannuzzi V; Bonifazi F
Front Med (Lausanne); 2023; 10():1113460. PubMed ID: 37521350
[TBL] [Abstract][Full Text] [Related]
16. Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2.
Larrosa C; Mora J; Cheung NK
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509390
[TBL] [Abstract][Full Text] [Related]
17. Access to medicines for rare diseases: A European regulatory roadmap for academia.
Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM
Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633
[No Abstract] [Full Text] [Related]
18. Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy.
Julian E; Pavlovic M; Sola-Morales O; Gianfrate F; Toumi M; Bucher HC; Dierks C; Greiner W; Mol P; Bergmann JF; Salmonson T; Hebborn A; Grande M; Cardone A; Ruof J
Health Econ Rev; 2022 Nov; 12(1):54. PubMed ID: 36333433
[TBL] [Abstract][Full Text] [Related]
19. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
